Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| AstraZeneca | 9.40% | $260.08M | £208.42B | 28.43% | 80 Outperform | |
| HSBC Holdings | 8.67% | $239.81M | HK$1.99T | 45.10% | 80 Outperform | |
| Shell (UK) | 7.05% | $195.10M | £153.44B | 7.52% | 73 Outperform | |
| Unilever | 4.69% | $129.82M | £105.45B | -7.82% | 72 Outperform | |
| British American Tobacco | 4.28% | $118.39M | £92.11B | 41.64% | 71 Outperform | |
| Rolls-Royce Holdings | 4.19% | $115.81M | £92.13B | 102.63% | 71 Outperform | |
| GlaxoSmithKline | 3.33% | $92.07M | £73.63B | 37.23% | 77 Outperform | |
| BP p.l.c. | 3.11% | $86.17M | £67.22B | 10.94% | 71 Outperform | |
| Rio Tinto | 2.90% | $80.24M | £96.55B | 14.06% | 82 Outperform | |
| Barclays | 2.82% | $77.99M | £61.63B | 64.94% | 78 Outperform |